April 3, 2024
PreciseDx to Attend the 2024 Annual National Comprehensive Cancer Network Conference
Focused on Changing Breast Cancer Outcomes
PreciseDx® is dedicated to supporting more personalized and precise treatments for breast cancer.
On average, every two minutes a woman is diagnosed with breast cancer in the United States.
About 1 in 8 U.S. women (about 2.3 million diagnosed annually) will develop invasive breast cancer over the course of their lifetime.
About PreciseDx
PreciseDx® is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.
Integrating artificial intelligence, lab processes and workflow systems
Transforming clinical modeling, patient phenotyping, and image analysis
Providing unmatched insights to support pathologists, and oncologists
Better Data. Better Outcomes.
PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum.
- Patients
- Providers
- Payers
- BioPharma
The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.
For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.
By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.
The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.
Patients
The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.
Providers
For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.
Payers
By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.
BioPharma
The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.
Gold Corporate Member
Jack Zeineh, PreciseDx
Gold Corporate Member
Featured News & Resources
Media Alert
Press Release
April 2, 2024
UCLA and PreciseDx Announce New Collaboration to Advance AI-Enabled Predictions and Risk Mitigation for Triple-Negative Breast Cancer Recurrence
Poster
March 22, 2024
EBCC-14 Poster: Clinical validation of an artificial-intelligent (AI) enabled digital test using the patient’s diagnostic breast biopsy to predict invasive breast cancer recurrence within 6-years.
Press Release
March 22, 2024
PreciseDx Presents New Research on Their AI-Enabled Digital Test at 14th Annual European Breast Conference
Press Release
December 22, 2023
PreciseDx Collaborates with Baylor Scott & White Health to Validate PreciseBreast™ Assessment for Early-Stage Invasive Breast Cancer Detection
Media Coverage
November 14, 2023
Clinical Lab Products
Digital Morphology Solution Predicts Breast Cancer Recurrence
Media Alert
April 3, 2024
PreciseDx to Attend the 2024 Annual National Comprehensive Cancer Network Conference
Press Release
April 2, 2024
UCLA and PreciseDx Announce New Collaboration to Advance AI-Enabled Predictions and Risk Mitigation for Triple-Negative Breast Cancer Recurrence
Poster
March 22, 2024
EBCC-14 Poster: Clinical validation of an artificial-intelligent (AI) enabled digital test using the patient’s diagnostic breast biopsy to predict invasive breast cancer recurrence within 6-years.